Nanjing Hicin Pharmaceutical Management
Management criteria checks 4/4
Nanjing Hicin Pharmaceutical's CEO is Yuping Cao, appointed in May 2013, has a tenure of 11.58 years. directly owns 0.38% of the company’s shares, worth CN¥9.49M. The average tenure of the management team and the board of directors is 3.9 years and 3.9 years respectively.
Key information
Yuping Cao
Chief executive officer
CN¥410.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 11.6yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump
Aug 15
We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve
May 01Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues
Mar 08CEO
Yuping Cao (60 yo)
11.6yrs
Tenure
CN¥410,800
Compensation
Mr. Yuping Cao serves as Chairman of the Board and General Manager at Nanjing Hicin Pharmaceutical Co., Ltd. since May 19, 2013. He completed graduation from China Pharmaceutical University in pharmacy in...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 11.6yrs | CN¥410.80k | 0.38% CN¥ 9.5m | |
| Deputy GM & Director | 2.4yrs | CN¥196.30k | no data | |
| Secretary & Deputy GM | 2.4yrs | CN¥370.80k | no data | |
| Deputy General Manager | 5.4yrs | CN¥406.80k | 0.012% CN¥ 290.9k | |
| Accounting Supervisor | no data | no data | no data |
3.9yrs
Average Tenure
44.5yo
Average Age
Experienced Management: 300584's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 11.6yrs | CN¥410.80k | 0.38% CN¥ 9.5m | |
| Deputy GM & Director | 2.4yrs | CN¥196.30k | no data | |
| Chairman of the Supervisory Board | 5.4yrs | no data | 0.0027% CN¥ 66.5k | |
| Independent Director | 5.4yrs | CN¥96.00k | no data | |
| Supervisor | 5.4yrs | no data | no data | |
| Independent Director | 5.4yrs | CN¥96.00k | no data | |
| Independent Director | 1.6yrs | CN¥52.00k | no data | |
| Non-Independent Director | 2.4yrs | CN¥521.60k | no data | |
| Supervisor | 2.4yrs | no data | no data | |
| Director | 1.6yrs | CN¥210.80k | no data |
3.9yrs
Average Tenure
46.5yo
Average Age
Experienced Board: 300584's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 05:02 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanjing Hicin Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |
| Mengmeng Han | Ping An Securities Co. Ltd. |